Acumen Pharmaceuticals, Inc.
ABOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $36 | $67 | $130 | $122 |
| Short-Term Investments | $136 | $177 | $48 | $72 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $7 | $3 | $3 | $4 |
| Total Curr. Assets | $178 | $247 | $180 | $199 |
| Property Plant & Equip (Net) | $0 | $1 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $60 | $63 | $16 | $32 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $61 | $64 | $16 | $32 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $239 | $310 | $197 | $230 |
| Liabilities | – | – | – | – |
| Payables | $6 | $1 | $2 | $1 |
| Short-Term Debt | $0 | $1 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $22 | $11 | $6 | $4 |
| Total Curr. Liab. | $28 | $13 | $8 | $5 |
| LT Debt | $30 | $28 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $3 | $0 | $0 |
| Total NC Liab. | $30 | $30 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $1 | $0 | $0 |
| Total Liabilities | $57 | $43 | $8 | $5 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$325 | -$223 | -$170 | -$128 |
| AOCI | -$0 | $0 | -$1 | -$0 |
| Other Equity | $507 | $489 | $360 | $353 |
| Total Equity | $182 | $267 | $189 | $225 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $239 | $310 | $197 | $230 |
| Net Debt | -$6 | -$38 | -$130 | -$122 |